A US Food and Drug Administration (FDA) investigation of injection-site necrosis in some people who received the 23-valent pneumococcal vaccine has concluded that the benefits of the vaccine outweigh ...

Add Yahoo as a preferred source to see more of our stories on Google. Apr. 9—(StatePoint) Pneumococcal pneumonia is a potentially serious bacterial lung disease that can disrupt your life for weeks ...

Please provide your email address to receive an email when new articles are posted on . Although vaccines have reduced the burden of pneumococcal disease, pneumonia due to Streptococcus pneumoniae and ...

Many babies or young children now get the recommended pneumococcal vaccine series. It is also recommended for all adults age 50 and older who are not known to have previously received a pneumococcal ...

Vaxcyte Inc. (NASDAQ:PCVX) is one of the best stocks to buy and hold for the next 6 months. On February 11, Vaxcyte Inc. (NASDAQ:PCVX) confirmed the dosing of the first participants in its OPUS-3 ...

Please provide your email address to receive an email when new articles are posted on . Over the past several years, adult pneumococcal vaccine recommendations have evolved based on the development of ...

V116 elicited immune responses that were noninferior compared to PPSV23 for the 12 serotypes (or strains) common to both vaccines, as measured by serotype-specific opsonophagocytic activity (OPA) ...

—Among adults, coverage and preventable burdens were lowest for pneumococcal conjugate vaccine (PCV) 15 and highest for PCV31, with PCV21 preventing notable burdens of both acute respiratory ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVE™ (Pneumococcal ...

Pneumococcal pneumonia is a potentially serious bacterial lung disease that can disrupt your life for weeks and even land you in the hospital. Medical experts want you to know that there are steps you ...